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Epidemiological and treatment-related factors contribute to improved 1 
outcome of oropharyngeal squamous cell carcinoma in Finland 2 
 3 
Background: Treatment for oropharyngeal squamous cell carcinoma (OPSCC) has 4 
changed, as the proportion of HPV-related disease has increased. We evaluated 5 
nationwide information on its management and outcome during the treatment paradigm 6 
change period. 7 
Methods: We included all patients diagnosed and treated for OPSCC at the five Finnish 8 
university hospitals from 2000 to 2009. Patient records and pathology registries 9 
provided the clinicopathological data. p16 staining was performed on primary tumor 10 
samples of patients who had received treatment with curative intent. 11 
Results: A total of 674 patients were diagnosed and treated for OPSCC, and the 12 
incidence increased along the study period. Of the evaluable tumors 58.5% were p16 13 
positive, and the number of p16-positive tumors increased along the years. The 14 
treatment was given with curative intent for 600 patients, and it was completed in 564. 15 
Of them, 47.9% underwent primary surgery and 52.1% received definitive oncological 16 
treatment. Also, the treatment protocol changed towards a more oncological approach. 17 
Among patients treated with curative intent the 5-year overall, disease-specific, and 18 
disease-free survival rates were 60.1%, 71.5%, and 57.0%. In multivariate analysis, 19 
p16-positivity seemed to relate to reduced disease mortality in lateral-wall and anterior-20 
wall disease. Depending on primary tumor localization, also sex, classes T3-4, presence 21 
of regional metastasis, and radiotherapy modality had an association with disease 22 
mortality.  23 
Conclusions: The incidence of p16-positive OPSCC and delivery of definitive 24 
oncological treatment increased in Finland during the study period. An improved 25 
survival outcome compared with the previous nationwide investigation was observed in 26 
this subset of patients.  27 
 28 
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Introduction 31 
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased 32 
during the last decades [1-4]. More precisely, the incidence rates for palatine tonsil (PT) 33 
 4 
and base of tongue (BOT) squamous cell carcinoma (SCC) have increased [1], and 1 
oncogenic human papilloma virus (HPV) infection is likely responsible for this trend 2 
[5]. Due to differences in cancer biology, the HPV-associated form of OPSCC is 3 
considered to be a distinct disease entity, whereas the HPV-negative OPSCC, with a 4 
declining incidence, is biologically more closely associated to other non-HPV-5 
associated HNSCCs [6]. In the carcinogenesis of HPV-associated OPSCC, the tumor 6 
suppressor protein, retinoblastoma, is inactivated. This leads to tumor suppressor 7 
protein p16 overexpression [7], which is used as an indirect surrogate marker for HPV 8 
association in OPSCC [8]. HPV-positive OPSCC, which has survival rates even 50% 9 
higher than its virus-negative counterparts [9], tends to present at a low T class, but with 10 
a more advanced N class resulting in a more advanced stage at diagnosis [10-12].  11 
There is a lack of consensus regarding the optimal management of OPSCC, as 12 
the outcome results after both definitive oncological treatment and combined treatment 13 
have been shown to be relatively similar [10, 13-16] The extent of treatment is typically 14 
adjusted according to factors such as disease stage, patients’ general condition, and 15 
comorbidity [17, 18]. Modifications of the treatment protocol, according to HPV status, 16 
should still be experimental [17-19], although the 8th Edition of UICC TNM 17 
classification characterizes OPSCC into two distinct subgroups depending on the HPV 18 
association of the tumor [20].  19 
Treatment planning warrants new perspectives, as HPV-positive OPSCC is 20 
suggested to have better survival regardless of treatment modality [10, 11]. According 21 
to studies by Ang et al. [5, 10], HPV status (or p16 status), smoking history, and T and 22 
N classes can be used to stratify OPSCC patients into three groups with characteristic 23 
overall survival rates. In addition, comorbidity may also be used to stratify OPSCC 24 
patients into three groups having distinct survival rates [21]. Several randomized studies 25 
 5 
evaluating the OPSCC treatment, especially in smaller tumors, are ongoing [22].  1 
In the history, both primary oncological approach and primary surgical approach 2 
have been considered as optimal treatment modalities for OPSCC, and the protocol 3 
shifts have been attributed to the advances in technology [23]. For some decades, at 4 
many centers, surgery used to have a more significant role in the treatment of OPSCC. 5 
Later on, delivery of definitive chemoradiotherapy has been increasing, reflecting an 6 
aim at better functional outcome as majority of patients remain without surgical 7 
intervention. [24, 25] However, surgery in treatment of a selected OPSCC patient group 8 
may also be beneficial and the rate of surgeries may be currently increasing [23].  9 
Head and neck cancer management is centralized to the five university hospitals 10 
in Finland, with a population of 5.5 million people. The Finnish Head and Neck 11 
Oncology Working Group maintains national treatment guidelines for these 12 
malignancies. The objective of this nationwide Finnish multicenter study is to describe 13 
the given treatments and patient outcome in an unselected series of OPSCC patients 14 
during the treatment paradigm change period over a 10-year period.  15 
 16 
Material and Methods 17 
Patients 18 
Our retrospective study population consisted of all patients with an OPSCC diagnosed 19 
and treated at one of the five Finnish university hospitals between January 1st 2000 and 20 
December 31st 2009. Only patients with an invasive squamous cell carcinoma (SCC) or 21 
its subtype were included. Data collection and p16 staining were retrospectively carried 22 
out. 23 
Patient records and pathology registries provided details on age, sex, tumor site, 24 
histology, grade of differentiation, TNM classification (UICC 7th Edition) [26], stage, 25 
 6 
intent of treatment, details on treatment (surgical treatment [Sx], radiotherapy [RT] 1 
chemotherapy, [CT], and chemoradiotherapy [CRT]), modality of RT (IMRT or 3D-2 
conformal), tumor recurrence, treatment of recurrent disease, and status at last follow 3 
up. The tumor sites were analyzed separately for the lateral wall (palatine tonsils, 4 
tonsillar fossa, and tonsillar pillars), anterior wall (base of tongue and vallecula), 5 
superior wall (soft palate and uvula), and posterior wall. We also included patients with 6 
subsequent follow up, or postoperative RT or CRT given at other hospitals. In these 7 
cases, postoperative oncological treatment was carried out according to the same 8 
national guidelines. The dates and causes of death were provided by Statistics Finland. 9 
A combination treatment (Sx + RT or CRT) was classified as complete if surgery was 10 
followed by postoperative RT of at least 45 Gy, and definitive RT or CRT were 11 
classified as complete if patients had at least 60 Gy of RT. CT was recorded if at least 12 
one cycle was implemented. Of all patients who received treatment with curative intent 13 
99% and 75% had a minimum of 3-year and 5-year follow-up or until death. This study 14 
was approved by the institutional Research Ethics Board (record number: 15 
179/13/03/02/2013) and a study permission was granted. 16 
 17 
Immunohistochemistry 18 
Formalin fixed paraffin blocks were collected from the pathology archives of each 19 
hospital. Among the patients with curative intent of treatment, 431 (71.8%) had their 20 
tumor block available for p16 immunohistochemistry. The tumor was regarded as p16 21 
positive if more than 70% of tumor cells were strongly immunopositive. 22 
 23 
Statistical analysis 24 
 7 
SPSS Version 20.0 (SPSS, Inc., Chicago, IL, USA) was used in the statistical analyses. 1 
The chi-square test with asymptotic or exact P-value explored the statistical associations 2 
of categorical variables. Independent samples T-test was used for continuous variables, 3 
and normal distribution was observed from histogram.  For survival analysis, we used 4 
the 3- and 5-year overall survival (OS), disease-specific survival (DSS), disease-free 5 
survival (DFS), and recurrence-free survival (RFS) in the Kaplan-Meier (KM) estimate. 6 
The statistical test of survival analysis was the Log rank test. The maximum length of 7 
follow-up was adjusted to five years to minimize the possibility of follow-up bias. 8 
Length of follow-up was calculated from the last day of treatment to the end of follow-9 
up, death of any cause (OS), or death of disease (DSS). DFS was calculated from the 10 
last treatment day to the detection of cancer recurrence at any site (primary, neck, or 11 
distant) or death of any cause. In RFS, only cancer recurrence was considered an 12 
endpoint, while other events were censored. The Cox proportional hazards model served 13 
in multivariate analysis. The proportional hazards assumption was tested with KM 14 
curves. Clinically relevant variables were selected into a manual backward stepwise 15 
multivariate analysis. Variables with a P-value less than 0.1 remained in the final step. 16 




Patient population 21 
A total of 674 patients with an invasive OPSCC or its histologic variant were identified 22 
(Figure 1). There were 500 (74.2%) males and 174 (25.8%) females, with the mean age 23 
of 58.5 years (range, 26.5 - 90.8). Sixty-one (9.1%) of them had a histological variant of 24 
OPSCC (lymphoepithelial SCC, basaloid SCC, adenosquamous SCC, papillar SCC, or 25 
 8 
verrucous SCC). The treatment was intended as curative for 600 (89.0%) patients and 1 
palliative for 74 (11.0%) patients. Treatment with curative intent remained incomplete 2 
for 36 patients and thus 564 patients obtained the planned treatment. During the study 3 
period, the annual number of OPSCC patients increased. During the years 2000-2004, 4 
260 new OPSCC patients were diagnosed, whereas during 2005-2009 the corresponding 5 
figure was 414.  6 
 7 
Patients having treatment with curative intent 8 
Table 1 shows the baseline clinical characteristics of the 600 patients who underwent 9 
treatment with curative intent in relation to p16 status, to the main treatment (Sx  10 
[C]RT or definitive [C]RT  Salvage Sx), and to the treatment years (2000-2004 or 11 
2005-2009). All patients went through magnetic resonance imaging and/or a computer 12 
tomography scan as a diagnostic procedure. Most tumors arose from the lateral wall of 13 
the oropharynx (64.5%). Of the lateral wall tumors from which p16 evaluation was 14 
available, most (68.4%) were p16 positive, which is contrary to the corresponding 15 
figures for superior (12.1%) and posterior wall tumors (25.0%). The percentage of p16-16 
positive and negative anterior wall tumors was almost equal (50.8% and 49.2%). In 17 
p16-positive OPSCC, patients had smaller primary tumors (T1-2), but the N class was 18 
more advanced resulting in a higher stage. In addition, p16-positive tumors had a higher 19 
histological grade, and patients carrying p16-positive tumors were more often non-20 
smokers. Patients, who had an anterior-wall OPSCC, or a class T4b tumor were most 21 
likely to receive definitive oncological treatment.  The incidence of p16-positive tumors 22 
increased, as during 2000-2004 there were 86 new p16-positive tumors (52.4% of the 23 
examined samples), and during 2005-2009 the number was 166 (62.2% of the examined 24 
samples). However, also the incidence of p16-negative tumors increased slightly.  In 25 
 9 
addition, treatment changed towards a more oncological approach (Supplementary 1 
Figure 1). 2 
 3 
Completed treatment with curative intent 4 
Surgery and postoperative oncological treatment 5 
Altogether 270 (47.9%) patients received primary surgery: Open surgery for the 6 
primary tumor was performed for 255 patients and endoscopic surgery for 14 patients as 7 
the first treatment. One patient underwent surgery to the neck only. The surgical defect 8 
was reconstructed with a microvascular tissue transfer or a pedicular flap in 139 9 
(51.5%) and 12 (4.4%) patients. A neck dissection (ND) was performed for 243 (92.4%) 10 
patients in pursuance of primary surgery. Twenty-three patients (8.5%) received surgery 11 
alone with no adjuvant therapy. Postoperative oncological treatment was given to 247 12 
(91.5%) patients: 142 received RT and 106 CRT. In postoperative RT and CRT, the 13 
prescribed median doses for the operated area were 66 and 60 Gy (range, 45-70 Gy, and 14 
50-70 Gy). An interruption of postoperative RT occurred in 29 patients. CRT was 15 
concomitant in all cases. The chemotherapeutic agent was cisplatin 40 mg/m2 weekly 16 
for 85 patients and 18 patients received 100 mg/m2 every third week. One patient 17 
received cetuximab and four received other chemotherapeutic agents. Only 57.4% of the 18 
patients received all planned cycles of postoperative CT. 19 
 20 
Definitive oncological treatment (± salvage surgery) 21 
Definitive oncological treatment was given to 294 (52.1%) patients. Two hundred and 22 
forty-nine (84.7%) patients received definitive CRT and 45 (15.3%) definitive RT. CRT 23 
was concomitant in 246 (98.8%) cases, whereas three patients received RT with 24 
adjuvant or neoadjuvant CT. The median prescribed dose to the macroscopic tumor was 25 
 10 
70 Gy (range, 60-74 Gy) in definitive CRT and 66 Gy (range, 60-72 Gy) in definitive 1 
RT. Ninety patients received conformal 3D RT and 199 IMRT, but in five patients the 2 
RT modality remained unknown. RT had to be interrupted in 48 patients. Of patients 3 
receiving concomitant CT, 203 received cisplatin 40 mg/m2 weekly, 13 cisplatin 100 4 
mg/m2 every third week, 6 cetuximab without cisplatin, while 21 received another type 5 
of CT without cisplatin. Reduction of CT doses or cycles due to side effects or other 6 
patient related factors occurred in 95 (38.6%) patients.  7 
 8 
Incomplete treatment with curative intent 9 
The treatment was classified incomplete in 36 (6.0%) patients. Of these, 23 patients had 10 
advanced OPSCC, Stage III-IV, but no oncological postoperative treatment was offered 11 
because of patient-related reasons such as severe comorbidities or patients refusal, or 12 
previous RT for a former head and neck malignancy. Postoperative RT was initiated, 13 
but not completed in one patient. Definitive RT was not carried out entirely up to the 14 
prescribed dose in 12 patients. 15 
 16 
Palliative treatment 17 
Of all patients, 74 (11.0%) primarily received palliative treatment. The disease stages 18 
were as follows: Stage II n=1; III n=2; IVA n= 30; IVB n=17; IVC n=18. The exact 19 
staging was not available for six patients. Palliative RT was delivered to 26 patients, 20 
palliative CT to four patients, palliative CRT to three patients, and boron neutron 21 
capture treatment to one patient. Two patients underwent palliative surgery. A total of 22 
38 patients received symptomatic treatment only. The median survival time in this 23 
patient population was 3.2 months (range, 0.1 – 35.5). 24 
 25 
 11 
Appearance of residual and recurrent disease 1 
A residual tumor (disease persistence within three months from treatment 2 
completion) appeared in 37 patients. Of them, six had undergone primary surgery and 3 
31 had undergone definitive oncological treatment. Out of all the 37 patients, 16 4 
underwent salvage surgery and five of them were alive with no evidence of disease after 5 
a median follow-up of 5 years (range, 4.6-5.0). Twenty-seven patients died of disease, 6 
and five of other causes. The median survival time among patients with a residual 7 
disease was 0.9 years (range, 0.0 – 4.9). 8 
Altogether 120 patients (20%) developed a recurrent disease within five years, 9 
and 84% of these occurred within three years. The recurrence was detected first at 10 
locoregional site in 76 patients, first at distant site in 38 patients, and concurrently at 11 
locoregional and distant sites in 6 patients.  A locoregional recurrence developed more 12 
often in patients with a p16-negative tumor. A distant recurrence developed nearly as 13 
often in patients with a p16-positive and p16-negative tumor (Supplementary Table 1). 14 
 15 
Outcome 16 
Treatment outcome after curative treatment intent 17 
The 3- and 5-year OS, DSS, and DFS rates are shown in Table 2. DSS stratified by T 18 
class, N class, stage, p16, and treatment are presented in Figure 2. Patients carrying a 19 
p16-positive tumor had a better 5-year DSS (81.0%) than those with a p16-negative 20 
tumor (57.2%). In addition, the group who underwent primary surgery as part of their 21 
treatment had a better 5-year DSS (76.3%) compared with to the group receiving 22 
definitive oncological treatment (66.7%). We also analyzed the p16-positive and p16-23 
negative groups separately (Figure 3): Among the p16-positive subgroup, patients 24 
carrying T1-3 tumors had a better DSS than those with T4 tumors. Regarding N class, 25 
 12 
N1-N2b classes had a minimal impact on survival compared with N0.  In the 1 
p16-negative subgroup, only patients with a T1 tumor showed a relatively good DSS (3-2 
year DSS 93.0%). DSS was poor regardless of N class (3-year DSS varying between 3 
76.3 - 0.0% among the N0-N3 classes). Of patients who underwent primary surgery 39 4 
(18.1%) had positive surgical margins. All these patients received postoperative 5 
oncological treatment. We analyzed the effect of surgical margins on DSS. Positive 6 
surgical margins did not impair the DSS (Supplementary Figure 2.)  7 
 8 
 9 
Survival in lateral and anterior OPSCC according to treatment approach (Table 3) 10 
Patients with lateral wall tumors treated with Sx + RT and Sx + CRT had a good 11 
prognosis; 3-year DSS reaching 86.3% and 93.0%. The corresponding figures for 12 
definitive CRT or CRT + Sx were 79.0% and 80.4%. The patients who had anterior wall 13 
tumors and received CRT had a better prognosis than those who underwent primary 14 
surgery as part of their treatment. 15 
 16 
Multivariate analysis of various patient, tumor, and treatment related factors (Table 4) 17 
Multivariate analysis is presented separately for patients with lateral and anterior wall 18 
OPSCC, because a statistically significant interaction occurred between primary tumor 19 
localization and treatment (definitive CRT  Salvage Sx vs. Sx + (C)RT) (P = 0.013), 20 
primary tumor localization and RT modality (3D conformal RT vs. IMRT) (P = 0.001), 21 
and primary tumor localization and N class (P = 0.037). Due to low incidence of 22 
superior and posterior wall OPSCC, patients having tumors at these sites were not 23 
included in multivariate analysis. In lateral wall OPSCC, p16 negativity, presence of 24 
regional metastasis, and male sex were associated with increased 5-year disease 25 
 13 
mortality. In anterior wall OPSCC, p16 negativity, 3D conformal RT (in comparison to 1 






We conducted a ten-year survey of all OPSCC patients treated at the five university 8 
hospitals to evaluate the treatment outcome in a nationwide series of 674 patients. 9 
During the study period the annual number of OPSCC patients increased, as a result of 10 
increase in the p16-positive cases. 11 
This study is a continuum to the earlier nationwide retrospective cohort study 12 
including all patients diagnosed and treated at the five Finnish university hospitals 13 
between 1995 - 1999 [27]. In the earlier series, the 5-year DSS of patients with lateral 14 
wall tumors was 73%, compared to present our 75%. The 5-year DSS of patients with 15 
an anterior wall OPSCC had improved slightly from 47% to 65% (Table 2). In the 16 
1990s, surgery followed by radiotherapy was the mainstay of treatments for OPSCC 17 
patients in Finland, as up to 85% of all patients had surgery for their primary tumors 18 
[27]. Consistent with other reports [24, 25], during the last years of this study, definitive 19 
oncological treatment became a standard (Supplementary Figure 1). Surgery still has a 20 
significant role for many of these patients, and the actual rate of surgeries did not 21 
decrease during the study period. In our material, 49% of patients treated with a curative 22 
intent, underwent primary surgery, which despite the changing trends in the 23 
management has been suggested to have an important role e.g. in HPV or p16-negative 24 
tumors [28, 29] and in patients having a history of heavy smoking [29]. During the same 25 
 14 
period, the number of HPV-related (p16-positive) OPSCC has increased in the Western 1 
World [30-32]. This increase may largely explain the improved survival figures, as 2 
HPV-related OPSCC has a more favorable prognosis [9]. Introduction of the IMRT 3 
technique and CRT in the beginning of the study period may also have impacted the 4 
survival figures.  5 
The multivariate analysis of our patient series was performed without patients 6 
carrying a T4b tumor or receiving RT or Sx only in order to eliminate patients with 7 
obvious selection bias. The analysis revealed three interactions suggesting a separate 8 
analysis for lateral-wall and anterior-wall disease. Both in lateral-wall disease and in 9 
anterior-wall disease p16-positivity seemed to be associated with decreased risk of 10 
disease mortality. In addition, patients who had a lateral-wall disease and neck 11 
metastasis, or were males seemed to have impaired DSS. CRT  Salvage Sx vs. Sx + 12 
(C)RT had a HR of 1.8, but the observation remained non-significant (P = 0.073). 13 
However, the finding was significant in a model without the backward elimination. The 14 
role of surgery in the management of tonsillar disease may only be speculated, and it 15 
should be further evaluated in a prospective randomized controlled setting. However, 16 
also the possible negative effect of combined vs. single modality treatment needs further 17 
investigation. In anterior-wall disease, patients who carried a large tumor (T3-4), were 18 
treated with conformal 3D RT (when compared with IMRT), or were males, had a 19 
significantly impaired DSS. In anterior-wall disease the main treatment modality (CRT 20 
 Salvage Sx vs. Sx + (C)RT) did not have any impact on DSS after adjustment of 21 
confounders. Most these patients received definitive oncological treatment, and only 22 
one fourth underwent Sx + (C)RT. The use of Sx + (C)RT in the treatment of anterior 23 
wall OPSCC decreased during the study period, as the use of CRT for the same site 24 
increased (data not shown). During our study period, robotic surgery was not available 25 
 15 
and more research is needed to sort out its role, especially in the treatment of small 1 
primary tumors. Statistically significant interactions between treatment related factors 2 
remained absent. 3 
In our material, positive surgical margins on histology did not have a statistically 4 
significant effect on survival (Supplementary Figure 2). All pertinent surgical 5 
procedures in the present series were carried out with the aim at achieving clear 6 
microscopic margins. Nevertheless, positive surgical margins still occurred in one fifth 7 
of the cases. Some earlier reports have also suggested that even non-radical surgery may 8 
improve survival in tonsillar SCC [33, 34]. We may therefore speculate that oncological 9 
treatment may be more efficacious on microscopic residual tumor cells when the 10 
primary tumor has been macroscopically resected.  11 
Our results showed that as compared with conventional RT, IMRT was 12 
significantly associated with improved outcome among patients with p16-negative 13 
tumors (Supplementary Figure 2). Patients with p16-positive tumors had favorable 14 
outcome regardless of RT method (Supplementary Figure 2). Likewise, Loimu et al. 15 
have previously presented good outcome in patients with a base of tongue OPSCC 16 
treated with IMRT [35]. Thus, improved outcome among patients with anterior wall 17 
OPSCC might be linked to the IMRT and introduction of CRT, and not only to the 18 
increase of p16-positive disease. Treatment with definitive CRT also offered a better 19 
outcome than only definitive RT, as previously reported comprehensively [36]. 20 
Some studies had pointed out that the UICC 7th Edition TNM classification of 21 
malignant tumors alone reflected poorly OPSCC survival [5, 10, 21, 37]. It had also 22 
been suggested, that the TNM staging would establish a prognostic value mainly among 23 
HPV-negative patients [38]. However, current 8th Edition of the UICC TNM 24 
classification of malignant tumors divides OPSCC into two categories according to p16 25 
 16 
status, which probably will aid survival estimation in patients belonging either to p16-1 
positive or to p16-negative subgroups [20]. In the current 8th UICC Edition, among p16-2 
positive OPSCC, classes T4a and T4b and N1-N2b are combined [20]. Our results 3 
indicated that amongst patients with a p16-positive OPSCC, markedly impaired survival 4 
was seen among patients with a large primary tumor (T4 class), but although number of 5 
patients with a T4b tumor was small, these patients had clearly worse outcome than 6 
those with a T4a tumor. The outcome of patients with p16-positive N0-N2b disease was 7 
relatively good, and the outcome was impaired only among patients with N2c or N3 8 
disease, which matches well with the current 8th Edition of UICC TNM classification. 9 
However, the number of patients with N3 tumor was also too small to draw any firm 10 
conclusions. Among patients with p16-negative OPSCC only those with stage I disease 11 
had a relatively good survival rate, and the outcome gradually worsened with more 12 
advanced T and N classes. Interestingly, those patients who had stage II p16-negative 13 
OPSCC clearly had a poor outcome suggesting that they may have been either 14 
undertreated or under staged. This same phenomenon, showing poor survival among 15 
patients with stage II tumors has previously been observed in studies of laryngeal cancer 16 
[39]. Possibly the current N classification for all p16-negative HNSCC aids the survival 17 
evaluation in p16-ngeative OPSCC, as the N classification is largely based on the 18 
occurrence of extranodal extension [20]. 19 
Despite national treatment guidelines, the treatment is always individually 20 
tailored causing some variations between given treatments. All patients are not suitable 21 
for obtaining CRT, and in such cases surgery with postoperative RT may be a more 22 
appropriate treatment option. Notably, in about one third of the patients receiving 23 
definite CRT it was not possible to administrate all cycles of CT. RT is not considered 24 
an optimal treatment for large necrotic lymph nodes, even though RT or CRT might 25 
 17 
otherwise be the recommended treatment option [40]. The theoretical basis for this is 1 
that tumors containing large amounts of hypoxic cells are more resistant to radiotherapy 2 
[41]. For those patients presenting with a large necrotic lymph node metastasis - and 3 
typically with a small p16-positive primary tumor - surgery, possibly neck dissection 4 
(ND) alone, followed by CRT or RT is often carried out at our institutions. 5 
This study presents a large unselected, nationwide and consecutive series of all 6 
OPSCC patients treated in Finland. Due to the national health care system, all patients 7 
had equal access to treatment, and therefore the socioeconomic factors affecting the 8 
treatment selection are limited. Furthermore, the five Finnish university hospitals have 9 
similar treatment facilities and patient compliance to follow-up is generally good. Due 10 
to the retrospective nature of this study, some clinical data, like information on smoking 11 
history, remained partly limited. In addition, tumor tissue unavailability limited p16-12 
status determination, as it was available in only 72% of the patients. Our data suffered 13 
from these limitations and from lack of a comorbidity or performance index. Therefore, 14 
comparison between treatment methods must be done with special caution as selection 15 
bias may be present. p16 and smoking status had a significant correlation (Gamma 16 
Value -0.808) with each other. In addition, smoking data was fairly limited, and 17 
especially the number of non-smokers was limited in anterior-wall disease resulting in 18 
extensive confidence intervals. Thus, we excluded smoking status from the multivariate 19 
analysis. The p16 status did not have an effect on the chosen treatments since it was 20 
very rarely available at the time of treatment decision. In addition, our study remained 21 
as survival data evaluation, and lacked evaluation of functional outcome.  22 
In conclusion, we demonstrated that from 2000 to 2009, the incidence of 23 
OPSCC increased countrywide, which occurred along with the increase in the number 24 
of patients with p16-positive tumors. These patients had a better survival rate than those 25 
 18 
with p16-negative tumors, which is in accordance with previous studies. Along with the 1 
increased incidence, treatment had changed towards to a more oncological approach. In 2 
anterior-wall disease a decrease in the rate of surgical treatment with concurrent 3 
improvement in the outcome was observed. This improved outcome was mainly 4 
associated with p16 positivity but also with developments in oncological treatment. In 5 
lateral-wall disease, the rate of surgical treatment remained higher throughout the study 6 
period. The role of surgery in the management of OPSCC disease requires further 7 
investigation.  8 
 9 
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Table 1. Baseline clinical characteristics of the 600 oropharyngeal squamous cell carcinoma patients treated with curative 


































Sex    0.745*   0.012*   0.651* 
 Men 442 188 136  203 239  170 272  
 Women 158 64 43  91 67  64 94  
Age  56.8 60.6 <0.001** 58.5 58.4 0.904** 57.5 59.0 0.075** 
Localization    <0.001***   <0.001*   0.946* 
 Lateral 387 186 86  213 174  154 233  
 Anterior 152 60 58  51 101  58 94  
 Superior 47 4 29  29 18  17 30  
 Posterior 14 2 6  1 13  5 9  
T class    0.013*   <0.001*   0.445* 
 T1 155 69 35  89 66  55 100  
 T2 208 98 62  111 97  84 124  
 T3 109 43 40  48 61  47 62  
 T4a 106 35 37  43 63  35 71  
 T4b 22 7 5  3 19  13 9  
N class    0.003*   0.052*   0.208* 
 N0 142 38 56  72 70  59 83  
 N1 122 50 41  66 56  53 69  
 N2a 90 53 15  45 45  38 52  
 N2b 176 81 43  90 86  53 123  
 N2c 56 24 21  14 42  26 30  
 N3 14 6 3  7 7  5 9  
Stage    <0.001*   0.002*   0.316* 
 I  33 6 17  23 10  16 17  
 II 63 19 25  33 30  26 37  
 24 
 III 108 46 33  58 50  44 64  
 IVA 362 169 96  179 192  132 230  
 IVB 34 12 8  10 24  16 18  
Smoking    <0.001*   0.043*   0.282* 
 Never 118 77 5  64 54  42 76  
 Earlier  134 74 25  67 67  48 86  
 Current 227 55 113  98 129  93 134  
 Unknown 121 N/A N/A        
Grade    <0.001*   0.701*   0.534* 
 1 49 12 25  25 24  16 33  
 2 188 66 74  89 99  70 118  
 3 223 125 48  114 109  85 138  
Unknown 140 N/A N/A        
p16       0.899*   0.046* 
 Positive 252 N/A N/A  135 117  86 166  
 Negative 179 N/A N/A  97 82  78 101  
Treatment    0.899*      <0.001* 
 Sx  (C)RT 294 135 97  N/A N/A  145 149  
 (C)RT  Sx 306 117 82  N/A N/A  89 217  
Years      0.046*   <0.001*    
 2000-2004 234 86 78  145 89  N/A N/A  
 2005-2009 366 166 101  149 217  N/A N/A  
* = Chi square test with asymptotic P value, ** = Independent samples T-test, *** = Chi square test with exact P value, Sx 
 (C)RT = Surgery  (chemo)radiotherapy, (C)RT  Sx = (Chemo)radiotherapy  salvage surgery 
 1 
Table 2. The 3- and 5-year overall (OS), disease-specific (DSS), and disease-
free survival (DFS) of patients with curative treatment intent. 
 No. of 
patients 
OS (%) DSS (%) DFS (%) 
All patients 3 yrs. 600 70.2 76.7 66.0 
All patients 5 yrs.  60.1 71.5 57.0 
Lateral wall 3 yrs. 387 75.8 81.5 70.6 
Lateral wall 5 yrs.  64.3 75.4 61.9 
Anterior wall 3 yrs. 152 59.2 66.9 56.6 
Anterior wall 5 yrs.  56.8 64.9 52.2 
n=number of patients     
 2 
Table 3. The 3-year overall (OS), disease specific (DSS), and disease-free survival (DFS) in 
lateral (tonsillar and tonsillar pillars) and anterior wall (base of tongue and vallecula) 
 25 
oropharyngeal squamous cell carcinoma according to treatment approach. 
  Lateral wall  Anterior wall 
 No. of 
patients 
OS(%) DSS(%) DFS(%) 
No. of 
patients 
OS(%) DSS(%) DFS(%) 
All 387 75.8 81.5 70.6 152 59.2 66.9 56.6 
Sx 17 47.1 50.7 23.5 14 35.7 42.9 28.6 
Sx+RT 105 78.9 86.3 77.0 26 57.7 66.8 57.7 
Sx+CRT 91 87.7 93.0 85.5 11 63.6 63.6 63.6 
RT 29 51.7 59.3 48.3 5 0.0 20.0 0.0 
RT+Salvage 
Sx 
8 62.5 62.5 62.5 2 50.0 50.0 50.0 
CRT 88 73.7 79.0 65.6 65 69.2 77.1 64.6 
CRT+Salvage 
Sx 
46 80.4 84.4 71.7 29 58.6 68.1 58.6 
Sx = Surgery, RT = Radiotherapy, CRT = Chemoradiotherapy, n=number of patients 




Table 4. Multivariate cox regression analysis for 5-year overall and disease specific survival of patients with 
lateral (tonsillar and tonsillar pillars) and anterior wall (base of tongue and vallecula) oropharyngeal 
squamous cell carcinoma. 
  Overall survival  Disease-specific survival 
  P HR 95% CI  P HR 95% CI 
Lateral wall         
No. of patients 226    224    
Age  0.051 1.0 1.0-1.1     
Male vs Female  0.042 2.2 1.0-4.6  0.016 5.8 1.4-24.2 
T3-4 vs T1-2  0.073 1.6 1.0-2.6     
N+ vs N0      0.029 9.2 1.2-68.0 
p16- vs p16+  <0.001 3.0 1.9-5.0  <0.001 4.4 2.3-8.5 
CRT ± Salvage Sx vs Sx + 
(C)RT 
 0.071 1.6 1.0-4.6  0.073 1.8 0.9-3.5 
         
Anterior wall         
No. of patients 99    98    
Male vs Female  0.068 2.2 0.9-5.1  0.028 3.9 1.2-13.5 
 26 
T3-4 vs T1-2  0.002 3.0 1.5-6.0  0.016 2.7 1.2-12.5 
p16- vs p16+  <0.001 3.6 1.7-7.3  0.021 2.6 1.2-5.7 
3D vs IMRT  <0.001 5.2 2.6-10.3  <0.001 5.5 2.4-12.5 
All models are adjusted with Age, Sex, T class, N class, p16, treatment (Sx + (C)RT = Surgery + 
(chemo)radiotherapy vs. CRT ± Sx = Chemoradiotherapy ± Salvage surgery), and radiotherapy modality (3D 
= 3D conformal radiotherapy vs IMRT = Internsity-modulated radiotherapy)  
HR = Hazard ratio, CI = Confidence interval 
 1 
